![]() The vaccine contains Novavax’s (Nasdaq: NVAX) Matrix-M, a saponin-based adjuvant that enhances the immune system response, making it more potent and more durable. Recent data from the large phase III trial also show high levels of efficacy and a reassuring safety profile. This followed 2021 results from the Phase-IIb trial reporting that R21/Matrix-M demonstrated high-level efficacy of 77%. Oxford researchers and their partners last year reported from a Phase IIb trial that a booster dose of R21/Matrix-M at one year following a primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy. Results from these trials are expected to be reported later this year. The R21/Matrix-M vaccine was initially designed and developed at the University of Oxford and has undergone clinical trials in the UK, Thailand, and several African countries, including an ongoing phase III trial in Burkina Faso, Kenya, Mali and Tanzania that has enrolled 4,800 children. The R21/Matrix-M malaria vaccine is a low-dose vaccine that can be manufactured at mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to African countries which are suffering a significant malaria burden. As with the Oxford-AstraZeneca COVID-19 vaccine, our partnership with the Serum Institute of India has been key to successful very large-scale manufacturing and rapid development.’ I congratulate our superb clinical trial partners in Africa who have generated the dataset supporting the safety and efficacy of the vaccine in children. ‘This marks a culmination of 30 years of malaria vaccine research at Oxford with the design and provision of a high efficacy vaccine that can be supplied at adequate scale to the countries who need it most. Professor Adrian Hill, Chief investigator, R21/Matrix-M programme, and Director of the University of Oxford’s Jenner Institute at the Nuffield Department of Medicine, said: The R21/Matrix-M vaccine has demonstrated high levels of efficacy and safety in Phase II trials, including amongst children who received a booster dose of R21/Matrix-M at one year following a primary three-dose regime. It is hoped that this first crucial step will enable the vaccine to help Ghanaian and African children to effectively combat malaria. The vaccine has been approved for use in children aged 5 to 36 months, the age group at highest risk of death from malaria. ![]() SIIPL is the manufacturing and commercialisation license holder for the vaccine. The successful registration was notified to SIIPL by the FDA Ghana. This marks the first regulatory clearance for the R21/Matrix-M malaria vaccine for use in any country.
0 Comments
Leave a Reply. |